ExeVir Bio
Zwijnaarde
About ExeVir Bio
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections. The company is harnessing a llama-derived antibody technology platform to generate robust antiviral therapies providing broad protection against coronaviruses. They using a highly innovative and clinically validated VHH technology to develop treatments for viral infections that may pose a significant global threat. ExeVir Bio develops a rapid response platform for antivirals. This platform technology enables an agile response to new health threats thanks to its short throughput time to generate drug candidates. The resulting protein-based therapeutics are sufficiently stable and easy to produce at a reasonable cost to enable true global access. ExeVir Bio was founded in 2020 and is headquartered in Zwijnaarde, Belgium.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $77.8M
- Funding stage: Early Stage Venture
- Last round: Grant (Jun 2023)
- Website: exevir.com
- Phone: 750-495-334
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/exevir-bio-679 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.